The Virus Inside Almost Everyone -
And the Antibody That May Finally Stop It

A First-of-Its-Kind Antibody That Blocks Infection Entirely

The results were published in Cell Reports Medicine in February 2026 and picked up again by ScienceDaily in April after the full implications became clearer. The team at Fred Hutch, led by scientists in the vaccine and infectious disease division, used a mouse model engineered to carry human antibody genes. This is a critical technical detail: one of the persistent obstacles in developing EBV therapies has been that conventional antibodies derived from non-human sources trigger immune reactions against the therapy itself. A human-derived antibody sidesteps that problem entirely.

Using these humanized mice, the researchers systematically screened for antibodies that targeted two specific proteins on the surface of EBV: gp350, which the virus uses to attach to B cells, and gp42, which it uses to fuse with and enter them. Think of gp350 as the grappling hook and gp42 as the crowbar. Without both, the virus cannot get inside the cell where it does its damage. The screening produced two antibodies against gp350 and eight against gp42.

Fred Hutch has filed for intellectual property rights covering the antibodies identified in the study, and the team is now working with scientific collaborators and an industry partner to advance a potential therapy. The initial clinical target is post-transplant lymphoproliferative disorder (PTLD) - a life-threatening form of lymphoma that develops in immunocompromised patients when EBV, freed from normal immune surveillance, runs unchecked. But the implications extend considerably further.

How EBV Hides Inside You - And Why It's So Hard to Eliminate

Epstein-Barr is a herpesvirus - a family of double-stranded DNA viruses that have co-evolved with the human immune system for so long that they have become expert at evading it. Like all herpesviruses, EBV does not leave. Once it infects you, it establishes a permanent residence in a specific population of cells and enters a state called latency - a kind of viral dormancy in which it stops replicating actively but keeps its genetic material circling inside the cell's nucleus as a small circular loop of DNA called an episome.

EBV's specific hiding place is the B lymphocyte - the very immune cells responsible for producing antibodies to fight infections. This is not a coincidence. B cells are long-lived, are distributed throughout the body, and renew themselves through cell division - which means that when the virus tethers itself to a B cell's chromosomes, every daughter cell carries the viral DNA as well. The virus has effectively hitched a permanent ride on your immune system's own maintenance machinery.

The mechanism by which EBV establishes this latency is remarkable. When the virus first infects a B cell, it does something biologically extraordinary: it immortalizes it. Normal B cells have a finite lifespan - they eventually die by a programmed process called apoptosis. EBV infection switches this off. The infected B cells begin dividing indefinitely, driven by viral proteins that hijack the cell's growth controls. The immune system of a healthy person usually brings this under control - this process of viral B cell immortalization is what you experience as mononucleosis, the "kissing disease" of adolescence, characterized by the swollen lymph nodes, fever, and exhaustion that result from a massive immune response to these newly immortalized cells.

After the acute phase passes, the immune system beats the virus back into dormancy. But not elimination. EBV retreats into a small pool of resting, latently infected memory B cells, where it expresses almost no viral proteins - making it essentially invisible to immune surveillance. There it will stay, occasionally reactivating and shedding into saliva, for the rest of the host's life.

From Lymphoma to Multiple Sclerosis: What EBV Actually Causes

EBV was the first human virus ever identified as a cancer-causing agent. It was discovered in 1964 by Michael Epstein and Yvonne Barr in cells taken from Burkitt lymphoma, an aggressive cancer of the jaw and abdomen that was devastating children in equatorial Africa. The discovery that a virus could drive malignant transformation was, at the time, a conceptual earthquake.

In the decades since, the list of EBV-associated malignancies has grown steadily. Hodgkin lymphoma, where EBV is present in the tumor cells of roughly 40 percent of cases. Nasopharyngeal carcinoma - a cancer of the back of the throat common in Southeast Asia - where EBV is present in virtually 100 percent of cases. A subset of gastric (stomach) cancers, accounting for roughly 10 percent of all gastric cancer diagnoses worldwide. NK/T-cell lymphomas. Post-transplant lymphoproliferative disorders. The oncogenic mechanism varies by cancer type, but the common thread is the virus's ability to drive uncontrolled cell proliferation, suppress apoptosis, and evade immune elimination.

The connection to multiple sclerosis - a neurological disease affecting roughly 2.8 million people worldwide, with no known cure - emerged with particular force in 2022. A landmark study published in Science by Bjornevik and colleagues followed more than 10 million young adults in the US military with serial blood samples spanning two decades. Of 955 individuals who developed MS during the study period, virtually all had been infected with EBV before their diagnosis. More striking: the risk of developing MS increased 32-fold after EBV infection, but did not increase after infection with other viruses - including cytomegalovirus, which is transmitted the same way and is similarly common. The serum levels of neurofilament light chain, a biomarker of nerve damage, began rising only after EBV seroconversion, not before.

The suspected mechanism is molecular mimicry: EBV encodes proteins that structurally resemble proteins in the myelin sheath - the insulating layer around nerve fibers that MS progressively destroys. An immune response initially aimed at the virus may become misdirected against the body's own myelin. This is not proven definitively, but the epidemiological signal from the military study was strong enough to shift scientific consensus from "associated" to "likely causal."

If This Works, the Implications Reach Far Beyond Transplant Medicine

The immediate clinical pathway for the Fred Hutch antibodies runs through transplant medicine. When a person receives an organ transplant, they are placed on immunosuppressive drugs to prevent rejection. These drugs also suppress the normal immune surveillance that keeps latent EBV in check. In some patients - particularly those who were EBV-negative before the transplant and then receive an organ from an EBV-positive donor - the virus begins to replicate unchecked, driving B cell proliferation into a full lymphoma. PTLD kills. The researchers envision an antibody infusion administered prophylactically to high-risk transplant patients as a way of preventing EBV activation before it begins.

But the longer arc is about what a neutralizing EBV antibody could mean for everyone else. If EBV is truly causal in multiple sclerosis - if the 32-fold risk increase seen in the military study reflects genuine disease induction and not just correlation - then blocking primary EBV infection could, in principle, prevent a proportion of MS cases. Moderna has been developing an mRNA vaccine targeting EBV gp350, similar in approach to the COVID-19 mRNA vaccines. The Fred Hutch antibodies offer a complementary, and potentially more powerful, approach: rather than teaching the immune system to generate its own blocking antibodies, you simply administer a pre-made one that is already proven to work.

There are obstacles remaining. Lab models with human immune systems are not human clinical trials. The antibodies will need to progress through safety studies, dose optimization, and eventually randomized trials. The question of how long antibody protection lasts, and whether re-dosing would be needed, is open. And the commercial and logistical challenges of deploying an EBV preventive therapy globally - in a world where the virus is transmitted casually and infects most people in childhood - are enormous.

But the scientific problem that has stumped researchers for sixty years - how do you stop a virus that has evolved to be essentially invisible to the immune system, hiding inside the very cells that are supposed to hunt it? - now has a candidate answer. You stop it before it ever gets through the door. You target gp42. And if the antibody identified at Fred Hutch performs in clinical trials the way it performed in the lab, the diseases that follow from that initial infection - the lymphomas, the MS, the decades of latent damage - may one day be preventable.